Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

The patent, Albumin Binding Domain Fusion Proteins No ... that may leverage the beneficial characteristics of binding to human serum albumin.” SON-1010, or IL-12-F H AB, the company’s lead ...

Albumin is the most abundant protein in the circulation. Its main physiologic function is to maintain colloid osmotic pressure. Better understanding of albumin's other physiologic functions has ...

Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline ...

Albumin-adjusted calcium formulas were not associated with greater accuracy in assessing serum calcium levels than unadjusted total calcium.

Association between blood–urea–nitrogen-to-albumin ratio and in-hospital mortality in patients diagnosed with coronavirus ...

Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

engineered for high-affinity subnanomolar binding to human PCSK9 and fused to human serum albumin to enhance plasma half-life. Following the FDA BLA filing, LIB is anticipating a Marketing ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (F H ...